P

PBS Biotech

Single-use bioreactors for cell therapy

Document Control and Training Associate

Part-TimeUpdated on 10/23/2026
$19.82 - $25.52/hr
Junior
Camarillo, CA, USA
In PersonPrimarily on-site at the Camarillo headquarters.
Biology & BiotechRegulatory & Quality (Life Sciences)

About the job

Requirements
  • At least 1 year of experience in a role requiring a high degree of quality control, ideally involving GMP quality systems, medical device (QSR/ISO 13485), aerospace (AS 9100), ISO 9001, or similar systems, or equivalent education such as a bachelor's degree.
  • Proficiency with Microsoft Word, Excel, PowerPoint, Outlook, and PDF fill-in forms.
  • Strong verbal and written communication and presentation skills.
  • Ability to meet physical requirements including clear vision, hearing, speech, and writing; manual dexterity; occasional standing, reaching, and lifting; and lifting up to 25 pounds as needed.
Responsibilities
  • Support the company’s cGMP qualification and ISO 9001:2015 certification efforts.
  • Support day-to-day Document Change Management, including document formatting, template creation and management, document and record distribution, and archival when applicable.
  • Help manage document control processes and systems to comply with internal procedures, policies, and regulatory requirements, including updating and coordinating with the ERP system.
  • Partner with identified staff to create and manage document format and content templates.
  • Assist with the Periodic Review program to ensure controlled documents are periodically reviewed for relevance and accuracy, reflect actual practices as defined in applicable procedures, and adhere to applicable regulatory standards.
  • Help maintain and enhance records management systems, including storage, retrieval, retention, and destruction.
  • Help manage physical and electronic document storage, including creating electronic copies, scanning records, managing incoming documentation and records, and record reconsolidation.
  • Help maintain the training program.
  • Send timely training notifications and follow up.
  • Monitor and support the creation and revision of training job roles, curriculum, and requirements.
  • Assist with managing and enhancing the electronic Learning Management System (LMS) and electronic document management system (EDMS), and provide user navigation support.
  • Maintain inspection readiness and participate in inspection preparation activities.
  • Support internal and external audits and inspections by retrieving and providing requested Quality Management System records and data in a timely manner.
  • Support Quality Management System initiatives as assigned.
  • Perform additional tasks and projects as needed to meet business objectives.
Desired Qualifications
  • Experience with a Quality Management System (QMS) and electronic Quality Management System (eQMS) is a strong plus.

About the company

PBS Biotech designs, manufactures, and sells single-use bioreactor systems and offers process development and technical support for cell therapy manufacturing. Its core Vertical-Wheel technology provides gentle, homogeneous mixing suitable for shear-sensitive cells like iPSCs and MSCs, enabling scalable suspension or microcarrier culture from research to clinical production. The company operates a B2B model, supplying equipment and disposable components along with customized process development services to academic, biotech, and pharmaceutical customers. With an ISO 9001:2015 certified facility and plans to scale to over $100 million in annual revenue, PBS Biotech aims to expand manufacturing capacity to support commercialization of cell therapies.

Company Size

51-200

Company Stage

Late Stage VC

Total Funding

$49M

Headquarters

Camarillo, California

Founded

2006

Get referred to PBS Biotech

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • PBS raised $17 million in January 2025 and expanded manufacturing for $100 million revenue.
  • MiniPRO expanded availability in August 2026, signaling product-market pull for process-development customers.
  • PBS won Life Sciences Review's 2026 award and deepened partnerships with Rockwell and denovoMATRIX.

What critics are saying

  • MiniPRO shipping depends on fragile cell-therapy capital spending and customer adoption in 2026.
  • Customer concentration in cell therapy ties revenue to biotech funding cycles and clinical setbacks.
  • If Rockwell or larger automation vendors replicate Vertical-Wheel economics, PBS loses its wedge.

What makes PBS Biotech unique

  • Vertical-Wheel bioreactors create low-shear mixing for iPSCs, MSCs, and NK cells.
  • MiniPRO runs 24 parallel vessels with Rockwell FactoryTalk, linking development to GMP.
  • Martin Simonetti, Brian Lee, and ex-Thermo Fisher operators give PBS deep execution credibility.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Flexible Work Hours

Growth & Insights and Company News

6 month growth

0%

1 year growth

2%

2 year growth

4%
PR Newswire
Sep 29th, 2026
PBS Biotech accelerates cell therapy development with Rockwell Automation technology

PBS Biotech has integrated Rockwell Automation technology into its MiniPRO bioreactor platform to accelerate cell therapy development. The system features up to 24 independently controlled bioreactors and uses FactoryTalk software to deliver real-time process control. The platform addresses industry challenges including low-throughput workflows and non-standardised environments that slow progress in Advanced Therapeutic Medicinal Products development. By embedding industrial-grade automation during product development, the system enables seamless progression to clinical and commercial manufacturing. The Advanced Regenerative Manufacturing Institute adopted the platform, noting that integration with existing control systems is streamlined due to Rockwell's standardised technology. PBS Biotech has demonstrated consistent process performance between the MiniPRO and its larger-scale Vertical-Wheel bioreactors, supporting predictable transfer into Good Manufacturing Practice settings.

Business Wire
Sep 16th, 2026
PBS Biotech Raises $10M to Provide Scale-Up Manufacturing Solutions for Cell Therapies

Single-use bioreactor manufacturer, PBS Biotech, recently closed a private $10M funding round with BroadOak Capital Partners. The financing will enable the c...

PR Newswire
Jul 21st, 2026
PBS Biotech wins 2026 cell Products Development of the Year award.

PBS Biotech wins 2026 cell Products Development of the Year award. Jul 21, 2026, 07:00 ET Recognition Highlights Company's Leadership in Advancing Linearly Scalable, Advanced Cell Therapy Manufacturing CAMARILLO, Calif., July 21, 2026 /PRNewswire/ - PBS Biotech, a leading developer of innovative single-use bioreactor technologies for cell therapy manufacturing, today announced it has been named Cell Therapy Products Development of the Year 2026 by Life Sciences Review. The company was also recognized among the publication's Top Companies in Cell and Gene Therapy, underscoring PBS Biotech's growing impact on the future of advanced therapeutic manufacturing. The recognition reflects PBS Biotech's continued commitment to helping cell therapy developers overcome one of the industry's greatest challenges: reliably scaling manufacturing while preserving cell quality and function. Through its patented Vertical-Wheel(R) bioreactor technology, PBS Biotech enables gentle, low-shear cell culture that supports the expansion and differentiation of a broad range of sensitive cell types, from early process development through commercial manufacturing. "As cell therapies continue to transform medicine, manufacturers need technologies that eliminate the traditional tradeoff between scalability and cell quality," said Martin Simonetti, Chief Executive Officer of PBS Biotech. "We're honored that Life Sciences Review has recognized our team's dedication to advancing manufacturing solutions that help bring life-changing therapies to patients faster." Unlike conventional stirred-tank bioreactors, PBS Biotech's Vertical-Wheel platform was specifically engineered to create homogeneous mixing with exceptionally low shear forces, providing an environment well suited for sensitive cell types including induced pluripotent stem cells (iPSCs), mesenchymal stem cells (MSCs), T cells, NK cells, CAR-T, CAR-NK, and pancreatic islet cells. The technology offers linear scalability from research through manufacturing, enabling customers to simplify process development and accelerate technology transfer. In its feature, Life Sciences Review highlighted PBS Biotech's customer-centric approach, commitment to innovation, and expanding collaborations across the cell and gene therapy ecosystem. The publication also recognized the company's role in helping developers address critical manufacturing bottlenecks as more cell therapies advance toward commercialization. "This recognition belongs to our employees, customers, collaborators, and partners who continue pushing the boundaries of regenerative medicine," Simonetti added. "Together, we're building the manufacturing foundation that will enable the next generation of cell therapies to reach more patients around the world." As demand for scalable, robust manufacturing platforms continues to grow, PBS Biotech remains focused on expanding its technology portfolio, supporting customer success, and advancing manufacturing solutions that accelerate the commercialization of transformative cell therapies. About PBS Biotech PBS Biotech is a biotechnology company dedicated to advancing the manufacture of next-generation cell therapies through innovative bioreactor technologies. Its patented Vertical-Wheel(R) bioreactor platform delivers gentle, low-shear mixing with scalable performance to support process development, clinical manufacturing, and commercial production. PBS Biotech partners with leading biotechnology companies, CDMOs, and academic institutions worldwide to accelerate the development and commercialization of life-changing cell therapies. About Forward-Looking Statements This press release contains forward-looking statements regarding PBS Biotech's future plans, expectations, and business outlook, including statements related to the development, adoption, and commercialization of cell therapy manufacturing technologies. These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. PBS Biotech undertakes no obligation to update any forward-looking statements as a result of new information, future events, or otherwise. Media Contact SOURCE PBS Biotech Inc.

FinSMEs
Jan 6th, 2025
PBS Biotech Raises $17M in Growth Funding

PBS Biotech raises $17M in Growth funding.

Pulse 2.0
Jan 6th, 2025
PBS Biotech Raises $17M for Growth

PBS Biotech raised $17 million in growth capital from Avego Management and BroadOak Capital Partners to enhance product innovation, process development, and quality systems. The company is expanding its ISO 9001:2015 manufacturing capacity to support over $100 million in annual revenue by mid-2025. PBS appointed Terrell Mathews as Chief Commercial Officer and Erik Wiberg as Chief Financial Officer to drive strategic growth and strengthen its market position in the cell therapy industry.